MedTrace Logo

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

NCT01907724 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2016-01-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolerability will also be assessed.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

IDX719

IDX719 will be supplied as a 50 mg tablet for oral administration.

DRUG

Simeprevir

Simeprevir will be supplied as 75 mg capsules for oral administration.

DRUG

TMC647055

TMC647055 will be supplied as 150 mg capsules for oral administration.

DRUG

RTV

RTV will be supplied as 80 mg/mL solution for oral administration.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907724 on ClinicalTrials.gov